Adverse event totals12

The totals the trial posted for each group.

1 to 12 of 12

Total	Group	Affected	At risk
Total, all-cause mortality	Double-blind Treatment Period: Placebo	0	6
Total, all-cause mortality	Double-blind Treatment Period: RVT-1401 340 mg/Week	0	5
Total, all-cause mortality	Double-blind Treatment Period: RVT-1401 680 mg/Week	0	6
Total, all-cause mortality	Open-label Extension Period: RVT-1401 340 mg Biweekly	0	15
Total, other adverse events	Double-blind Treatment Period: Placebo	5	6
Total, other adverse events	Double-blind Treatment Period: RVT-1401 340 mg/Week	4	5
Total, other adverse events	Double-blind Treatment Period: RVT-1401 680 mg/Week	5	6
Total, other adverse events	Open-label Extension Period: RVT-1401 340 mg Biweekly	10	15
Total, serious adverse events	Double-blind Treatment Period: Placebo	0	6
Total, serious adverse events	Double-blind Treatment Period: RVT-1401 340 mg/Week	0	5
Total, serious adverse events	Double-blind Treatment Period: RVT-1401 680 mg/Week	1	6
Total, serious adverse events	Open-label Extension Period: RVT-1401 340 mg Biweekly	1	15

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03863080/event-totals